Drugs / TPI 287
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT02187822 | Oct 2014 → Feb 2018 | metastatic malignant neoplasm in the brain | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02133846 | May 2014 → Sep 2019 | corticobasal degeneration disorder, corticobasal syndrome, progressive supranuclear palsy, tauopathy | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01966666 | Nov 2013 → Sep 2019 | Alzheimer disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01067066 | Feb 2010 → Jul 2016 | melanoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00867568 | Mar 2009 → Sep 2011 | medulloblastoma, neuroblastoma | Giselle Sholler | Completed | No outcome recorded |
| Phase 1 | NCT00256191 | Nov 2005 → Feb 2007 | Hodgkins lymphoma, non-Hodgkin lymphoma | Cortice Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00113724 | May 2005 → Jan 2008 | Hodgkins lymphoma, non-Hodgkin lymphoma | Cortice Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT01340729 | Sep 2013 → Sep 2016 | metastatic melanoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01933815 | Aug 2013 → Nov 2024 | glioblastoma | Cortice Biosciences, Inc. | Suspended | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01582152 | Jul 2012 → Mar 2016 | brain neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01483820 | Dec 2011 → Dec 2014 | medulloblastoma, neuroblastoma | Giselle Sholler | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01505608 | Dec 2011 → Dec 2014 | neuroblastoma | Giselle Sholler | Terminated | No outcome recorded Stop: Enrollment |
| Phase 25 trials | ||||||
| Phase 2 | NCT02047214 | Jan 2014 → Dec 2015 | glioblastoma | Cortice Biosciences, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01332630 | Aug 2011 → Apr 2017 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01113463 | Apr 2010 → Jun 2011 | brain cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00553813 | Oct 2007 → Sep 2009 | malignant pancreatic neoplasm | Cortice Biosciences, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00479635 | Jan 2007 → Aug 2008 | prostate cancer | Cortice Biosciences, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPI-287 | “TPI 287 is similar to a type of chemotherapy drug called a taxane and is designed to block a protein (tubulin) that helps the cancer cells divide.” NCT01582152 ↗18“Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma” NCT01483820 ↗ “the microtubule stabilizer TPI-287 (abeotaxane)” PMID 31710340 ↗ Feb 2020 |
| Action | Inhibit | “TPI 287 is designed to block tumors from growing by preventing cancer cells from dividing.” NCT01067066 ↗ |
| Modality | Small molecule | “a novel taxane analog” NCT00113724 ↗ |
| Route | Intravenous | “intravenous administration of TPI 287” NCT00113724 ↗ |